{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T18:32:18Z","timestamp":1791311538664,"version":"4.3.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2015,4,15]],"date-time":"2015-04-15T00:00:00Z","timestamp":1429056000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1186\/s12885-015-1287-9","type":"journal-article","created":{"date-parts":[[2015,4,14]],"date-time":"2015-04-14T07:04:10Z","timestamp":1428995050000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival"],"prefix":"10.1186","volume":"15","author":[{"given":"C\u00e9cile","family":"Borel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Lamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gis\u00e8le","family":"Compaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"R\u00e9cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Jeanneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Claude","family":"Nogaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bauvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Despas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Delpierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,4,15]]},"reference":[{"key":"1287_CR1","series-title":"vol 19","volume-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","author":"M Sant","year":"2010","unstructured":"Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project, vol 19. 2010."},{"issue":"4","key":"1287_CR2","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1002\/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I","volume":"38","author":"EM McKelvey","year":"1976","unstructured":"McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38(4):1484\u201393.","journal-title":"Cancer"},{"issue":"4","key":"1287_CR3","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235\u201342. doi:10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"issue":"5","key":"1287_CR4","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/S1470-2045(06)70664-7","volume":"7","author":"M Pfreundschuh","year":"2006","unstructured":"Pfreundschuh M, Tr\u00fcmper L, \u00d6sterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379\u201391. http:\/\/dx.doi.org\/10.1016\/S1470-2045(06)70664-7.","journal-title":"Lancet Oncol"},{"issue":"8","key":"1287_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3324\/haematol.2010.038109","volume":"96","author":"O Fitoussi","year":"2011","unstructured":"Fitoussi O, Belhadj K, Mounier N, Parrens M, Tilly H, Salles G, et al. Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA. Haematologica. 2011;96(8):1136\u201343. doi:10.3324\/haematol.2010.038109.","journal-title":"Haematologica"},{"issue":"9","key":"1287_CR6","first-page":"1281","volume":"90","author":"A Italiano","year":"2005","unstructured":"Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A. Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80\u00a0years old. Haematologica. 2005;90(9):1281\u20133.","journal-title":"Haematologica"},{"issue":"19","key":"1287_CR7","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24(19):3121\u20137. doi:10.1200\/jco.2005.05.1003.","journal-title":"J Clin Oncol"},{"issue":"2","key":"1287_CR8","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9(2):105\u201316. http:\/\/dx.doi.org\/10.1016\/S1470-2045(08)70002-0.","journal-title":"Lancet Oncol"},{"issue":"6","key":"1287_CR9","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO;2-T","volume":"66","author":"R Epelbaum","year":"1990","unstructured":"Epelbaum R, Faraggi D, Ben-Arie Y, Ben-Shahar M, Haim N, Ron Y, et al. Survival of diffuse large cell lymphoma. a multivariate analysis including dose intensity variables. Cancer. 1990;66(6):1124\u20139.","journal-title":"Cancer"},{"issue":"4","key":"1287_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s00277-007-0399-y","volume":"87","author":"A Bosly","year":"2008","unstructured":"Bosly A, Bron D, Van Hoof A, De Bock R, Berneman Z, Ferrant A, et al. Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHOP. Ann Hematol. 2008;87(4):277\u201383. doi:10.1007\/s00277-007-0399-y.","journal-title":"Ann Hematol"},{"issue":"8","key":"1287_CR11","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/oxfordjournals.annonc.a058619","volume":"4","author":"E Lepage","year":"1993","unstructured":"Lepage E, Gisselbrecht C, Haioun C, Sebban C, Tilly H, Bosly A, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol. Ann Oncol. 1993;4(8):651\u20136.","journal-title":"Ann Oncol"},{"issue":"5","key":"1287_CR12","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00277-008-0447-2","volume":"87","author":"R Pettengell","year":"2008","unstructured":"Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol. 2008;87(5):429\u201330. doi:10.1007\/s00277-008-0447-2.","journal-title":"Ann Hematol"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/1756-9966-28-116","volume":"28","author":"Y Terada","year":"2009","unstructured":"Terada Y, Nakamae H, Aimoto R, Kanashima H, Sakamoto E, Aimoto M, et al. Impact of relative dose intensity (RDI) in CHOP combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res. 2009;28:116. doi:10.1186\/1756-9966-28-116.","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"1287_CR14","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1007\/s00277-010-0956-7","volume":"89","author":"T Hirakawa","year":"2010","unstructured":"Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K. Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol. 2010;89(9):897\u2013904. doi:10.1007\/s00277-010-0956-7.","journal-title":"Ann Hematol"},{"issue":"9\u201310","key":"1287_CR15","first-page":"533","volume":"24","author":"R Epelbaum","year":"1988","unstructured":"Epelbaum R, Haim N, Ben-Shahar M, Ron Y, Cohen Y. Dose-intensity analysis for CHOP chemotherapy in diffuse aggressive large cell lymphoma. Isr J Med Sci. 1988;24(9\u201310):533\u20138.","journal-title":"Isr J Med Sci"},{"issue":"6","key":"1287_CR16","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.1990.8.6.963","volume":"8","author":"LW Kwak","year":"1990","unstructured":"Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol. 1990;8(6):963\u201377.","journal-title":"J Clin Oncol"},{"key":"1287_CR17","doi-asserted-by":"publisher","unstructured":"Wildiers H, Reiser M. Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncology\/Hematology. 2011;77(3):221\u201340. http:\/\/dx.doi.org\/10.1016\/j.critrevonc.2010.02.002.","DOI":"10.1016\/j.critrevonc.2010.02.002"},{"issue":"14","key":"1287_CR18","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/j.ejca.2008.06.011","volume":"44","author":"N Roswall","year":"2008","unstructured":"Roswall N, Olsen A, Christensen J, Rugbjerg K, Mellemkj\u00e6r L. Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994\u20132003. Eur J Cancer. 2008;44(14):2058\u201373. http:\/\/dx.doi.org\/10.1016\/j.ejca.2008.06.011.","journal-title":"Eur J Cancer"},{"issue":"16","key":"1287_CR19","doi-asserted-by":"publisher","first-page":"2786","DOI":"10.1016\/j.ejca.2006.04.018","volume":"42","author":"DP Cronin-Fenton","year":"2006","unstructured":"Cronin-Fenton DP, Sharp L, Deady S, Comber H. Treatment and survival for non-Hodgkin\u2019s lymphoma: Influence of histological subtype, age, and other factors in a population-based study (1999\u20132001). Eur J Cancer. 2006;42(16):2786\u201393. doi:http:\/\/dx.doi.org\/10.1016\/j.ejca.2006.04.018.","journal-title":"Eur J Cancer"},{"issue":"5","key":"1287_CR20","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1038\/bjc.2012.3","volume":"106","author":"BL Frederiksen","year":"2012","unstructured":"Frederiksen BL, Dalton SO, Osler M, Steding-Jessen M, de Nully BP. Socioeconomic position, treatment, and survival of non-Hodgkin lymphoma in Denmark - a nationwide study. Br J Cancer. 2012;106(5):988\u201395.","journal-title":"Br J Cancer"},{"issue":"23","key":"1287_CR21","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1182\/blood-2013-07-517110","volume":"123","author":"L Tao","year":"2014","unstructured":"Tao L, Foran JM, Clarke CA, Gomez SL, Keegan THM. Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era. Blood. 2014;123(23):3553\u201362.","journal-title":"Blood"},{"issue":"32","key":"1287_CR22","doi-asserted-by":"publisher","first-page":"5376","DOI":"10.1200\/JCO.2009.22.0038","volume":"27","author":"FR Loberiza","year":"2009","unstructured":"Loberiza FR, Cannon AJ, Weisenburger DD, Vose JM, Moehr MJ, Bast MA, et al. Survival disparities in patients with lymphoma according to place of residence and treatment provider: a population-based study. J Clin Oncol. 2009;27(32):5376\u201382. doi:10.1200\/jco.2009.22.0038.","journal-title":"J Clin Oncol"},{"key":"1287_CR23","doi-asserted-by":"crossref","unstructured":"23. Pornet C, Delpierre C, Dejardin O, Grosclaude P, Launay L, Guittet L et al. Construction of an adaptable European transnational ecological deprivation index: the French version. J Epidemiol Community Health. 2012. doi:10.1136\/jech-2011-200311.","DOI":"10.1136\/jech-2011-200311"},{"issue":"6","key":"1287_CR24","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5(6):649\u201355.","journal-title":"Am J Clin Oncol"},{"issue":"10","key":"1287_CR25","first-page":"3562","volume":"92","author":"JY Blay","year":"1998","unstructured":"Blay JY, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al. The international prognostic index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Blood. 1998;92(10):3562\u20138.","journal-title":"Blood"},{"issue":"14","key":"1287_CR26","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project","year":"1993","unstructured":"The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive Non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987\u201394. doi:10.1056\/nejm199309303291402.","journal-title":"N Engl J Med"},{"issue":"5","key":"1287_CR27","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857\u201361.","journal-title":"Blood"},{"issue":"5","key":"1287_CR28","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/S1470-2045(11)70069-9","volume":"12","author":"F Peyrade","year":"2011","unstructured":"Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile J-F, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12(5):460\u20138. http:\/\/dx.doi.org\/10.1016\/S1470-2045(11)70069-9.","journal-title":"Lancet Oncol"},{"issue":"21","key":"1287_CR29","doi-asserted-by":"publisher","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","volume":"22","author":"GH Lyman","year":"2004","unstructured":"Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of Low chemotherapy dose-intensity in aggressive Non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol. 2004;22(21):4302\u201311. doi:10.1200\/jco.2004.03.213.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1287_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1056\/NEJM198101013040103","volume":"304","author":"G Bonadonna","year":"1981","unstructured":"Bonadonna G, Valagussa P. Dose\u2013response effect of adjuvant chemotherapy in breast cancer. N Engl J Med. 1981;304(1):10\u20135. doi:10.1056\/NEJM198101013040103.","journal-title":"N Engl J Med"},{"issue":"11","key":"1287_CR31","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1200\/JCO.1984.2.11.1281","volume":"2","author":"W Hryniuk","year":"1984","unstructured":"Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2(11):1281\u20138.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1287_CR32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1111\/j.1365-2125.1980.tb05847.x","volume":"9","author":"JA Green","year":"1980","unstructured":"Green JA, Dawson AA, Fell LF, Murray S. Measurement of drug dosage intensity in MVPP therapy in Hodgkin's disease. Br J Clin Pharmacol. 1980;9(5):511\u20134.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"1287_CR33","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1177\/0193945911434518","volume":"34","author":"L Berben","year":"2012","unstructured":"Berben L, Dobbels F, Engberg S, Hill MN, De Geest S. An ecological perspective on medication adherence. West J Nurs Res. 2012;34(5):635\u201353. doi:10.1177\/0193945911434518.","journal-title":"West J Nurs Res"},{"issue":"8","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.ijnurstu.2011.01.008","volume":"48","author":"G Compaci","year":"2011","unstructured":"Compaci G, Ysebaert L, Ob\u00e9ric L, Derumeaux H, Laurent G. Effectiveness of telephone support during chemotherapy in patients with diffuse large B cell lymphoma: the ambulatory medical assistance (AMA) experience. Int J Nurs Stud. 2011;48(8):926\u201332. http:\/\/dx.doi.org\/10.1016\/j.ijnurstu.2011.01.008.","journal-title":"Int J Nurs Stud"},{"issue":"22","key":"1287_CR35","doi-asserted-by":"publisher","first-page":"5401","DOI":"10.1182\/blood-2008-12-196543","volume":"113","author":"L Noens","year":"2009","unstructured":"Noens L, van Lierde MA, De Bock R, Verhoef G, Zachee P, Berneman Z, et al. Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. Blood. 2009;113(22):5401\u201311. doi:10.1182\/blood-2008-12-196543.","journal-title":"Blood"},{"issue":"5","key":"1287_CR36","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1684\/bdc.2013.1738","volume":"100","author":"F Despas","year":"2013","unstructured":"Despas F, Roche H, Laurent G. [Anticancer drug adherence]. Bull Cancer. 2013;100(5):473\u201384. doi:10.1684\/bdc.2013.1738.","journal-title":"Bull Cancer"},{"issue":"4","key":"1287_CR37","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/1097-0142(19910215)67:4<945::AID-CNCR2820670415>3.0.CO;2-R","volume":"67","author":"SJ Schleifer","year":"1991","unstructured":"Schleifer SJ, Bhardwaj S, Lebovits A, Tanaka JS, Messe M, Strain JJ. Predictors of physician nonadherence to chemotherapy regimens. Cancer. 1991;67(4):945\u201351.","journal-title":"Cancer"},{"issue":"1","key":"1287_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3960\/jslrt.51.1","volume":"51","author":"H Yamaguchi","year":"2011","unstructured":"Yamaguchi H, Hirakawa T, Inokuchi K. Importance of relative dose intensity in chemotherapy for diffuse large B-cell lymphoma. J Clin Exp Hematop. 2011;51(1):1\u20135. doi:10.3960\/jslrt.51.1.","journal-title":"J Clin Exp Hematop"},{"key":"1287_CR39","doi-asserted-by":"crossref","unstructured":"39. Maurer MJ, Ghesqui\u00e8res H, Jais J-P, Witzig TE, Haioun C, Thompson CA et al. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2014. doi:10.1200\/jco.2013.51.5866.","DOI":"10.1200\/JCO.2013.51.5866"},{"issue":"3","key":"1287_CR40","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1634\/theoncologist.2013-0343","volume":"19","author":"B Lee","year":"2014","unstructured":"Lee B, Goktepe O, Hay K, Connors JM, Sehn LH, Savage KJ, et al. Effect of place of residence and treatment on survival outcomes in patients with diffuse large B-cell lymphoma in British Columbia. Oncologist. 2014;19(3):283\u201390. doi:10.1634\/theoncologist.2013-0343.","journal-title":"Oncologist"},{"issue":"1","key":"1287_CR41","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.respe.2010.10.008","volume":"59","author":"O Dejardin","year":"2011","unstructured":"Dejardin O, Berchi C, Mignon A, Pornet C, Guillaume E, Guittet L, et al. In\u00e9galit\u00e9s sociales, de sant\u00e9 du constat \u00e0 l\u2019action \u2013 Int\u00e9r\u00eat de la mise en place d\u2019un accompagnement personnalis\u00e9 pour la r\u00e9duction des in\u00e9galit\u00e9s sociales en canc\u00e9rologie. Rev Epidemiol Sante Publique. 2011;59(1):45\u201351. http:\/\/dx.doi.org\/10.1016\/j.respe.2010.10.008.","journal-title":"Rev Epidemiol Sante Publique"},{"issue":"4","key":"1287_CR42","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1136\/jech.2008.081117","volume":"64","author":"C Pornet","year":"2010","unstructured":"Pornet C, Dejardin O, Morlais F, Bouvier V, Launoy G. Socioeconomic determinants for compliance to colorectal cancer screening. a multilevel analysis. J Epidemiol Community Health. 2010;64(4):318\u201324. doi:10.1136\/jech.2008.081117.","journal-title":"J Epidemiol Community Health"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-015-1287-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1287-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-015-1287-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T11:09:02Z","timestamp":1630580942000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-015-1287-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4,15]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1186\/s12885-015-1287-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,4,15]]},"assertion":[{"value":"16 October 2014","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2015","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2015","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"288"}}